First Malaria Vaccine
Published: July 26, 2015
First Malaria Vaccine, The European Medicines Agency (EMA) has recommended the RTS,S malaria vaccine (Mosquirix-GlaxoSmithKline) as safe and effective to use in babies in Africa who are at risk for the deadly disease.
The vaccine, developed in partnership with the PATH Malaria Vaccine Initiative and also with funding from the Bill and Melinda Gates Foundation, would be the first licensed human vaccine against a parasitic disease. The World Health Organization is now set to review the vaccine, and it plans to offer guidance by year-end on when and where the vaccine could be used.
The vaccine would also have to be reviewed by regulators in any countries that wish to use it. While trial data released in 2011 and 2012 indicated that the vaccine decreased malaria episodes in babies aged 6-12 weeks by only 27% and by about 46% in those aged 5-17 months, EMA recommended that the vaccine be used in babies aged 6 weeks to 17 months. Malaria took the lives of about 584,000 people in 2013, most of them babies in sub-Saharan Africa.
Please feel free to send if you have any questions regarding this post , you can contact on